Vanguard Group Inc. Decreases Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)

Vanguard Group Inc. lowered its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 1.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,389,216 shares of the company's stock after selling 79,539 shares during the period. Vanguard Group Inc. owned about 5.89% of Arcus Biosciences worth $80,245,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Jane Street Group LLC boosted its holdings in Arcus Biosciences by 59.8% during the 3rd quarter. Jane Street Group LLC now owns 217,041 shares of the company's stock valued at $3,319,000 after acquiring an additional 81,193 shares during the period. Barclays PLC boosted its stake in shares of Arcus Biosciences by 49.0% during the third quarter. Barclays PLC now owns 118,693 shares of the company's stock valued at $1,816,000 after purchasing an additional 39,015 shares during the period. US Bancorp DE increased its stake in shares of Arcus Biosciences by 2,432.0% in the fourth quarter. US Bancorp DE now owns 6,887 shares of the company's stock worth $103,000 after buying an additional 6,615 shares during the period. KLP Kapitalforvaltning AS bought a new stake in Arcus Biosciences during the 4th quarter valued at $207,000. Finally, Amundi grew its holdings in Arcus Biosciences by 137.0% in the 4th quarter. Amundi now owns 27,030 shares of the company's stock worth $403,000 after acquiring an additional 15,624 shares during the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

Several analysts recently issued reports on RCUS shares. Bank of America cut their target price on Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 19th. HC Wainwright raised Arcus Biosciences from a "neutral" rating to a "buy" rating and boosted their target price for the company from $18.00 to $24.00 in a research note on Wednesday, February 26th. Finally, Morgan Stanley dropped their price target on Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating for the company in a research note on Tuesday, February 18th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Arcus Biosciences currently has an average rating of "Buy" and an average price target of $30.25.

Insiders Place Their Bets

In related news, CEO Terry J. Rosen acquired 19,800 shares of Arcus Biosciences stock in a transaction that occurred on Thursday, February 27th. The stock was bought at an average price of $10.18 per share, with a total value of $201,564.00. Following the transaction, the chief executive officer now directly owns 2,554,160 shares in the company, valued at approximately $26,001,348.80. This represents a 0.78 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Yasunori Kaneko bought 20,000 shares of the company's stock in a transaction on Thursday, February 27th. The stock was bought at an average cost of $10.06 per share, for a total transaction of $201,200.00. Following the completion of the acquisition, the director now directly owns 28,400 shares of the company's stock, valued at approximately $285,704. This represents a 238.10 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 12.30% of the company's stock.

Arcus Biosciences Stock Up 2.1 %

RCUS stock traded up $0.16 during midday trading on Tuesday, hitting $7.84. The stock had a trading volume of 454,398 shares, compared to its average volume of 778,035. The business has a 50-day moving average of $9.58 and a two-hundred day moving average of $13.53. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The firm has a market cap of $824.28 million, a price-to-earnings ratio of -2.49 and a beta of 1.54. Arcus Biosciences, Inc. has a 52-week low of $6.50 and a 52-week high of $18.98.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, topping analysts' consensus estimates of ($1.17) by $0.14. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The firm had revenue of $36.00 million for the quarter, compared to the consensus estimate of $29.38 million. As a group, equities research analysts forecast that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.